Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis

Adding ICIs to CT or CRT significantly improves survival outcomes in advanced or recurrent CC, particularly in PD-L1-positive patients. However, the increased risk of grade 3-5 AEs underscores the need for vigilant toxicity monitoring and management. These findings highlight the potential of ICIs to enhance immune-mediated tumor control, offering a promising therapeutic option for selected patient populations.